Researchers compared outcomes related to three direct oral anticoagulant (DOAC) care models.
Catalent, which is being acquired by Novo, reports 10% drop in second-quarter revenue
Four days after Novo Holdings announced plans to buy Catalent for $16.5 billion, the CDMO revealed its financial health in its fiscal second quarter. Catalent